Labetalol Medication Template PDF

Preview

Summary

Labetalol ATI Medication Template...

Description

ACTIVE LEARNING TEMPLATE:

Medication

Silvia Ayala STUDENT NAME _____________________________________ Labetalol MEDICATION __________________________________________________________________________

REVIEW MODULE CHAPTER ___________

Beta Blocker - antianginal - antihypertensives CATEGORY CLASS ______________________________________________________________________ PURPOSE OF MEDICATION

Expected Pharmacological Action • Blocks stimulation of beta1 (myocardial)- and beta2 (pulmonary, vascular, and uterine)-adrenergic receptor sites. • Also has alpha1-adrenergic blocking activity, which may result in more orthostatic hypotension.

Therapeutic Use Decreased BP.

Complications CNS: fatigue, weakness, anxiety, depression, dizziness, drowsiness, insomnia, memory loss, mental status changes, nightmares. CV: ARRHYTHMIAS,BRADYCARDIA, HF, orthostatic hypotension. Derm: itching, rash. EENT: blurred vision, dry eyes, intraoperative floppy iris syndrome, nasal stuffiness. Endo: hyperglycemia, hypoglycemia. GI: constipation, diarrhea, nausea. GU: erectile dysfunction, libido. MS: arthralgia, back pain, muscle cramps. Neuro: paresthesia. Resp: PULMONARY EDEMA, bronchospasm, wheezing.

Contraindications/Precautions Contraindicated in: • Decompensated HF; • PE • Cardiogenic shock; • Bradycardia or heart block. Use Cautiously in: • Renal or hepatic impairment; • Pulmonary disease (including asthma); • Diabetes mellitus (may mask signs of hypoglycemia); • Thyrotoxicosis (may mask symptoms); • Patients with a history of severe allergic reactions • OB: Recommended for treatment of chronic hypertension (PO) or hypertensive emergency in pregnancy (IV); may cause fetal/neonatal bradycardia, hypotension, hypoglycemia, or respiratory depression; • Pedi: Safety and effectiveness not established in children

Interactions • • • • • • • • • •

General anesthesia and verapamil may cause additive myocardial depression. Additive bradycardia may occur with digoxin, verapamil, or diltiazem. Additive hypotension may occur with other antihypertensives, acute ingestion of alcohol, or nitrates. Concurrent thyroid administration may effectiveness. May alter the effectiveness of insulin or oral hypoglycemic agents (dose adjustments may be necessary). May < the effectiveness of adrenergic bronchodilators and theophylline. May < beneficial beta cardiovascular effects of dopamine or dobutamine. Use cautiously within 14 days of MAO inhibitor therapy (may result in hypertension). Effects may be > by propranolol or cimetidine. Concurrent NSAIDs may < antihypertensive action.

Evaluation of Medication Effectiveness Decrease in BP.

ACTIVE LEARNING TEMPLATES

Medication Administration • (High Alert): Before administering intravenously, have second practitioner independently check original order, dosage calculations, and infusion pump settings. • PO: Take apical pulse prior to administering. If BUN, serum lipoprotein, potassium, triglyceride, an uric acid levels. • May cause > ANA titers. • May cause > in blood glucose levels. • May cause > serum alkaline phosphatase, LDH, AST, and ALT levels. Discontinue if jaundice or laboratory signs of hepatic function impairment occur.

Client Education • Instruct patient to take medication as directed, at the same time each day, even if feeling well • Advise patients to make position changes slowly to minimize orthostatic hypotension • Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected, or if breast feeding. • Advise patient to notify health care professional if slow pulse, difficulty breathing, wheezing, cold hands and feet, dizziness, light-headedness, confusion, depression, rash, fever, sore throat, unusual bleeding, or bruising occurs.

THERAPEUTIC PROCEDURE

A7...